Phase Ib/II trial of multiple escalating doses of ITI 007 for the treatment of patients with stable schizophrenia.
Phase of Trial: Phase I/II
Latest Information Update: 30 Jul 2010
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Intra-Cellular Therapies
- 30 Jul 2010 Primary endpoints of 'safety and tolerability' have been met; results reported in an Intra-Cellular Therapies media release.
- 30 Jul 2010 Status changed to completed according to Intra-Cellular Therapies media release
- 30 Jul 2010 Results have been reported in an Intra-Cellular Therapies media release.